Search Results | Cancer Research | American Association for Cancer Research

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Abstract CT175: Targeting inducible nitric oxide in a first-in-class phase 1/2 trial in triple-negative breast cancer patients diminishes M2 macrophage polarization and led to a robust clinical response

Cancer Res (2021) 81 (13_Supplement): CT175.

DOI: https://doi.org/10.1158/1538-7445.AM2021-CT175

Published: 01 July 2021

View article

Journal Articles

Abstract 3269: Metformin to prevent metabolic syndrome associated with androgen deprivation therapy (ADT): Metabolic analysis from a placebo-controlled study of metformin in non-diabetic men initiating ADT for advanced prostate cancer (PCa)

Devalingam Mahalingam, Salih Hanni, Christos Fountzilas, Joel Michalek, John Sarantopoulos, Sureshkumar Mulampurath Achuthan Pillai, John Kuhn, Michael Pollak, Ian Thompson

Cancer Res (2018) 78 (13_Supplement): 3269.

DOI: https://doi.org/10.1158/1538-7445.AM2018-3269

Published: 01 July 2018

View article

Journal Articles

Phase I Clinical Investigation of 9-β-d-Arabinofuranosyl-2-fluoroadenine 5′-Monophosphate (NSC 312887), a New Purine Antimetabolite¹

John J. Hutton, Daniel D. Von Hoff, John Kuhn, Jerry Phillips, Marla Hersh, Gary Clark

Cancer Res (1984) 44 (9): 4183–4186.

Published: 01 September 1984

View article

Journal Articles

Phase I Clinical Investigation of 9,10-Anthracenedicarboxaldehyde Bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942)

Daniel D. Von Hoff, J. William Myers, John Kuhn, John F. Sandbach, Robert Pocelinko, Gary Clark, Charles A. Coltman, Jr.

Cancer Res (1981) 41 (8): 3118–3121.

Published: 01 August 1981

View article

Journal Articles

Phase I Clinical Investigation of 1,4-Dihydroxy-5,8-bis{{ {2-[(2-hydroxyethyl)amino]ethyl}amino}}-9,10-anthracenedione Dihydrochloride (NSC 301739), a New Anthracenedione

Daniel D. Von Hoff, Ester Pollard, John Kuhn, Edward Murray, Charles A. Coltman, Jr.

Cancer Res (1980) 40 (5): 1516–1518.

Published: 01 May 1980

View article

NARROW

Abstract CT175: Targeting inducible nitric oxide in a first-in-class phase 1/2 trial in triple-negative breast cancer patients diminishes M2 macrophage polarization and led to a robust clinical response

Abstract 3269: Metformin to prevent metabolic syndrome associated with androgen deprivation therapy (ADT): Metabolic analysis from a placebo-controlled study of metformin in non-diabetic men initiating ADT for advanced prostate cancer (PCa)

Phase I Clinical Investigation of 9-β-d-Arabinofuranosyl-2-fluoroadenine 5′-Monophosphate (NSC 312887), a New Purine Antimetabolite¹

Phase I Clinical Investigation of 9,10-Anthracenedicarboxaldehyde Bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942)

Phase I Clinical Investigation of 1,4-Dihydroxy-5,8-bis{{ {2-[(2-hydroxyethyl)amino]ethyl}amino}}-9,10-anthracenedione Dihydrochloride (NSC 301739), a New Anthracenedione

Email alerts

AACR Journals

Abstract CT175: Targeting inducible nitric oxide in a first-in-class phase 1/2 trial in triple-negative breast cancer patients diminishes M2 macrophage polarization and led to a robust clinical response

Abstract 3269: Metformin to prevent metabolic syndrome associated with androgen deprivation therapy (ADT): Metabolic analysis from a placebo-controlled study of metformin in non-diabetic men initiating ADT for advanced prostate cancer (PCa)

Phase I Clinical Investigation of 9-β-d-Arabinofuranosyl-2-fluoroadenine 5′-Monophosphate (NSC 312887), a New Purine Antimetabolite1

Phase I Clinical Investigation of 9,10-Anthracenedicarboxaldehyde Bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (CL216,942)

Phase I Clinical Investigation of 1,4-Dihydroxy-5,8-bis{{ {2-[(2-hydroxyethyl)amino]ethyl}amino}}-9,10-anthracenedione Dihydrochloride (NSC 301739), a New Anthracenedione

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Phase I Clinical Investigation of 9-β-d-Arabinofuranosyl-2-fluoroadenine 5′-Monophosphate (NSC 312887), a New Purine Antimetabolite¹